Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Follicular Lymphoma Clinical Trial

Official title:

A Randomised Multicentre Trial of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy in Combination With Rituximab (Mabthera®) for Stage I - II Low Grade Follicular Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00115700
• Other study ID #: TROG 99.03
• Secondary ID: ALLG NHLLOW5
• Status: Completed
• Phase: Phase 3
• Start date: February 2000
• Est. completion date: August 2018

Study information

• Verified date: November 2022
• Source: Trans Tasman Radiation Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with stage I and II low grade follicular lymphoma are randomised between standard therapy (involved field radiotherapy) and investigational therapy (involved field radiotherapy and chemotherapy plus rituximab). The main endpoint is progression free survival but overall survival and the influence of t(14;18) status will also be studied.

Description:

Radiotherapy is the only modality which has been proven to have curative potential in patients with localised low grade lymphoma. Despite excellent control of the local tumour, most patients relapse outside the area treated with radiation and most of these ultimately die from lymphoma. This study tests the hypothesis that the addition of six cycles of chemotherapy plus rituximab (systemic chemotherapy) can eradicate undetectable lymphoma deposits outside the radiation field and thereby improve the cure rate. The study will specifically test the hypothesis that six cycles of adjuvant CVP chemotherapy (cyclophosphamide, vincristine, prednisolone) in combination with Rituximab will improve progression-free survival for patients with stage I and II low-grade follicular lymphoma treated with involved-field radiotherapy (IFRT). That is, will patients given radiotherapy plus systemic chemotherapy live longer or remain free from disease longer than patients treated with radiation alone? Radiotherapy alone is widely regarded as the standard treatment for this disease.

There are a number of secondary endpoints to the study, as follows:

1. Comparison the pre- and post-treatment prevalence of the t(14:18) translocation, in peripheral blood and bone marrow, of patients treated with either IFRT alone or IFRT plus chemotherapy. This translocation is potentially a marker for minimal residual disease and eradication of the marker from blood cells may have prognostic implications. The clinical value of "molecular remission" as an early predictor of freedom from progression (FFP) and survival will be assessed.

2. Comparison of overall survival and FFP for patients treated with IFRT alone with overall survival and FFP for patients treated with combined IFRT and systemic therapy. Delay of progression of disease may be of limited value if overall survival is the same.

3. Comparison of acute and late toxicity and second malignancy rates for patients treated with IFRT or IFRT plus systemic therapy.

4. Delineation of the location of first relapse in relation to radiation therapy fields.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: August 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (= 18 years old) with histologically documented "follicular lymphoma, grade 1", grade 2", or "follicular lymphoma, grade 3a" diagnosed following an excisional, incisional or generous core biopsy. (i.e. an FNA alone is insufficient.)

• Disease limited to stages I and II after adequate staging

• Anticipated life expectancy > 5 years

• Given written informed consent

• Been assessed by a radiation oncologist and a medical oncologist/ haematologist

• WCC > 3.0 x 10^9/L, platelet count > 100 x 10^9/L, serum creatinine < 0.15 mmol/L

• Ability to commence radiotherapy within 6 weeks of randomisation

• Women using effective contraception, are not pregnant and agree not to become pregnant during participating in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter.

Exclusion Criteria:

• Received previous systemic cytotoxic chemotherapy.

• Received previous radiotherapy, (except superficial radiation therapy for non-melanoma skin cancers).

• Received previous immunotherapy.

• A medical contraindication to radiotherapy, chemotherapy, or rituximab.

• Any previous or concurrent malignancy other than curatively treated non-melanoma skin cancer, level 1 malignant melanoma, or in situ cervical cancer, unless disease and treatment-free for 5 years.

• Such extensive involvement of the thorax that treatment with radiation therapy alone would be hazardous because of excessive lung irradiation, even if a shrinking field technique were employed.

• Suspected or confirmed pregnancy. Must not be lactating.

• Patients who have known human immuno-deficiency virus (HIV) infection or active hepatitis B (HBV).

• Treatment within a clinical study within 30 days prior to study entry.

Related Conditions & MeSH terms

• Follicular Lymphoma
• Lymphoma
• Lymphoma, Follicular

Intervention

Drug:
• Cyclophosphamide
1000 mg/m2 I.V. on day 1

Radiation:
• Radiotherapy
The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.

Drug:
• Vincristine
1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
• Prednisolone
50 mg/m2 orally daily for days 1 - 5
• Rituximab
375 mg/m2 IV Infusion day 1

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital	Adelaide	South Australia
Australia	St John of God Hospital	Ballarat	Victoria
Australia	Peter MacCallum Cancer Centre	East Melbourne	Victoria
Australia	The Canberra Hospital	Garran	Australian Capital Territory
Australia	Andrew Love Cancer Care Centre, Geelong Hospital	Geelong	Victoria
Australia	Austin Health	Heidelberg	Victoria
Australia	Launceston General Hospital	Launceston	Tasmania
Australia	Sir Charles Gairdner Hospital	Nedlands	Western Australia
Australia	Calvary Mater Newcastle	Newcastle	New South Wales
Australia	Prince of Wales Hospital	Randwick	New South Wales
Australia	Radiation Oncology - Mater Centre	South Brisbane	Queensland
Australia	Genesis Cancer Care (previously Premion)	Tugun	Queensland
Australia	Westmead Hospital	Wentworthville	New South Wales
Australia	Albury Base/Murray Valley Private Hospital	West Albury	New South Wales
Australia	Illawarra Cancer Care Centre	Wollongong	New South Wales
Australia	The Queen Elizabeth Hospital	Woodville	South Australia
Australia	Princess Alexandra Hospital	Woolloongabba	Queensland
Canada	Princess Margaret Hospital	Toronto
New Zealand	Auckland Hospital	Auckland
New Zealand	Waikato Hospital	Hamilton
New Zealand	Wellington Hospital	Wellington

Sponsors (2)

Lead Sponsor	Collaborator
Trans Tasman Radiation Oncology Group	Australasian Leukaemia and Lymphoma Group

Countries where clinical trial is conducted

Australia,  Canada,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival (PFS). Period from the date of randomisation to 1st progression of disease or death from any cause.		Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual. Long term follow-up analysis is planned after 10 years of follow-up
Secondary	Pre- and post-treatment prevalence of the t(14;18) translocation, in peripheral blood and bone marrow between arms		Peripheral blood at commencement of treatment, after 1 year and upon relapse is collected and stored for later analysis to be done as part of translational studies when funding becomes available
Secondary	Overall Survival (OS)	Period from date of randomisation to date of death from any cause.	Main analysis will be done on completion of 5 years follow-up after the end of accrual. An interim analysis to be done after at least 3 years of follow-up. A futility analysis will be performed after the 5 year analysis. In the absence of futility being
Secondary	Location of first relapse	Period from date of randomisation to date of first relapse location via CT scan and or other imaging as required	Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual
Secondary	To compare time to evolution to higher histological grade	Period from date of randomisation to date of higher histological grade via CT scan and or other imaging as required	Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual
Secondary	Freedom from progression.	Period from date of randomisation to date of first disease progression.	Main analysis after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual. Long term follow-up analysis is planned after 10 years of follow-up
Secondary	Acute and late toxicities and secondary malignances		Frame after at least 3 years of follow-up following the end of accrual. An updated analysis may be done on completion of 5 years follow-up after the end of accrual

External Links

•   Click here for more information about this study on the TROG official website